Is aggressive cholesterol control justified? review of the post–coronary artery bypass graft trial

The Post–Coronary Artery Bypass Graft (CABG) trial was undertaken to compare the efficacy of aggressive low-density-lipoprotein (LDL) cholesterol lowering (<85 mg/dL) with moderate LDL-cholesterol lowering (130–140 mg/dL) in preventing atherosclerotic